<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Decreased function of the exocrine pancreas is frequent in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Our aim was to investigate clinical correlates of pancreatic exocrine failure in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: We investigated exocrine function by assaying both elastase-1 concentration and chymotrypsin activity in 667 patients </plain></SENT>
<SENT sid="3" pm="."><plain>We conducted separate analysis on patients with Type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> and patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were separated into three groups according to whether both elastase-1 concentration and chymotrypsin activity were <z:mpath ids='MPATH_458'>normal</z:mpath>, or one or both were altered </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: A total of 667 consecutive patients were analysed, including 195 with Type 1 and 472 with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Elastase-1 concentration was &lt;200 Î¼g/g in 23% of the patients </plain></SENT>
<SENT sid="7" pm="."><plain>Chymotrypsin activity was &lt;6 U/g in 26% of the patients </plain></SENT>
<SENT sid="8" pm="."><plain>In 66% of the patients elastase-1 concentration was &gt;200 ug/g and chymotrypsin activity &gt;6 U/g </plain></SENT>
<SENT sid="9" pm="."><plain>One test was below threshold in 19%, both in 15% </plain></SENT>
<SENT sid="10" pm="."><plain>In patients with Type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, the three groups defined by results of elastase-1 concentration and chymotrypsin activity differed with regard to duration of <z:mp ids='MP_0002055'>diabetes</z:mp> and prevalence of glutamic acid decarboxylase antibodies, but not BMI or HbA(1c) , or prevalence of <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, <z:hpo ids='HP_0000112'>nephropathy</z:hpo> or <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>In patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, the three groups differed with regard to BMI, use of insulin and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e>, but not known duration </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Factors associated with pancreatic exocrine failure differ in patients with Type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> compared with patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="13" pm="."><plain>In patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, association of decreased pancreatic exocrine function with BMI and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> suggests a role of pancreatic <z:e sem="disease" ids="C0852949" disease_type="Disease or Syndrome" abbrv="">arteriopathy</z:e> </plain></SENT>
</text></document>